Grifols SA ADR (GIKLY)
Grifols, S.A. is a Spanish healthcare company focused on plasma-derived medicines and related healthcare solutions. Through its subsidiaries, the group develops, produces, and markets therapies and products used in immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology. Its activities are organized into four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
The company also supplies diagnostic testing equipment, reagents, transfusion medicine products, clinical diagnostics, and testing services. In addition, it provides biological materials and intermediate plasma products to pharmaceutical, biotechnology, and life-science customers, along with hospital solutions such as intravenous therapies, clinical nutrition, automation systems, and medical devices for several specialized care areas. Grifols was founded in 1909 and is headquartered in Barcelona, Spain.
The security listed under OTC Markets is an ADR, representing depositary receipt exposure to the company’s common stock rather than an ordinary operating share on the local exchange.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-GIKL.Y
|
$6.90
|
20.0% Upside
|
Undervalued
|
Not available
|
Not available
|
Great
|
1.9%
|
November 10, 2026
|
12.6x
|
1.0x
|
0.8x
|
6.607 B
|
18.921 B
|
53.7%
|
61.4%
|
6.9
|
28.3%
|
180.8%
|
